

APPENDIX D



US005772998A

United States Patent [19]

Dasch et al.

[11] Patent Number: 5,772,998

[45] Date of Patent: Jun. 30, 1998

[54] MONOCLONAL ANTIBODIES TO TRANSFORMING GROWTH FACTOR-BETA AND METHODS OF USE

[75] Inventors: James R. Dasch, Palo Alto; Doran R. Pace, III, San Francisco; Wendy O. Waegell, Mountain View, all of Calif.

[73] Assignee: Celtrix Pharmaceuticals, Inc., Santa Clara, Calif.

[21] Appl. No.: 434,976

[22] Filed: May 4, 1995

Related U.S. Application Data

[62] Division of Ser. No. 759,109, Sep. 6, 1991, Pat. No. 5,571,714, which is a continuation of Ser. No. 288,432, Dec. 22, 1988, abandoned.

[51] Int. Cl.⁶ A61K 39/395; C07K 16/22

[52] U.S. Cl. 424/133.1; 424/145.1; 424/158.1; 530/387.3; 530/388.23; 530/388.24; 530/389.2

[58] Field of Search 424/145.1, 158.1, 424/198.1, 133.1; 435/70.21, 172.2, 240.27; 530/388.23, 388.24, 389.2, 399, 387.3

[56] References Cited

U.S. PATENT DOCUMENTS

4,774,322 9/1988 Seyedin et al.

FOREIGN PATENT DOCUMENTS

0455482 11/1991 European Pat. Off.
WO 91/19513 12/1991 WIPO
WO 94/18991 9/1994 WIPO

OTHER PUBLICATIONS

Roberts et al., "Type β transforming growth factor: a bifunctional regulator of cellular growth" *Proc. Natl. Acad. Sci. USA* (1985) 82:119-123.Hayashi et al., "Differential effects of TGF- β_1 on lymphohemopoiesis in long-term bone marrow cultures" *Blood* (1989) 74(5):1711-1717.Carlino et al., "Transforming growth factor β_1 systematically modulates granuloid, erythroid, lymphoid, and thrombocytic cells in mice" *Exp. Hematol.* (1992) 20:943-950.Han et al., "Megakaryocytopoiesis: characterization and regulation in normal and pathologic states" *Int. J. Hematol.* (1991) 54(1):3-14.Ishibashi et al., "Type β transforming growth factor is a potent inhibitor of murine megakaryocytopoiesis in vitro" *Blood* (1987) 69:1737-1741.Keller et al., "Transforming growth factor β directly regulates primitive murine hematopoietic cell proliferation" *Blood* (1990) 75:596-602.Cashman et al., "Mechanisms that regulate the cell cycle of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF- β " *Blood* (1990) 75(1):96-101.Ellingsworth et al., "Antibodies to the N-terminal portion of cartilage-inducing factor A and transforming growth factor β " *J. Biol. Chem.* (1986) 261:12362-12367.Eaves et al., "Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer" *Blood* (1991) 78(1):110-117.Hatzfeld et al., "Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β_1 or Rb oligonucleotides" *J. Exp. Med.* (1991) 174:925-929.Wang et al., "Expression cloning and characterization of the TGF- β type III receptor" *Cell* (1991) 67:797-805.Jordan et al., "Cellular and developmental properties of fetal hematopoietic stem cells" *Cell* (1990) 61:953-963.Waegell et al., "Neutralizing antibody to TGF- β overcomes normal growth controls in long-term bone marrow cultures" *J. Cell. Biochem.* (1992) 16:92 (abstract No. M342).Dasch et al., "Monoclonal antibodies recognizing transforming growth factor- β . Bioactivity neutralization and transforming growth factor β_2 affinity purification" *J. Immunol.* (1989) 142:1536-1547.Herlyn et al., "Growth-regulatory factors for normal, premalignant, and malignant human cells in vitro" *Adv. Cancer Res.* (1990) 54:213-234.Harris et al., "Therapeutic antibodies—the coming of age" *TIBTECH* (1993) 11:42-44.Lucas et al., "The autocrine production of transforming growth factor- β_1 during lymphocyte activation" *J. Immunol.* (1990) 145:1415-1422.Galfrè et al., "Preparation of monoclonal antibodies: strategies and procedures" *Meth. Enzymol.* (1981) 73:3-46.Cheifetz et al., "The transforming growth factor- β system: A complex pattern of cross-reactive ligands and receptors" *Cell* (1987) 48:409-416.Ellingsworth et al., "Transforming growth factor- β s are equipotent growth inhibitors of interleukin-1-induced thymocyte proliferation" *Cell. Immunol.* (1988) 114:41-54.Kehrl et al., "Production of transforming growth factor- β by human T lymphocytes and its potential role in the regulation of T cell growth" *J. Exp. Med.* (1986) 163:1037-1050.Kehrl et al., "Transforming growth factor β is an important immunomodulatory protein for human B lymphocytes" *J. Immunol.* (1986) 137:3855-3860.Keller et al., "Transforming growth factor β -1 selectively regulates early murine hematopoietic progenitors and inhibits the growth of IL-3-dependent myeloid leukemia cell lines" *J. Exp. Med.* (1988) 168:737-750.Keski-Oja et al., "Immunodetection and modulation of cellular growth with antibodies against native transforming growth factor- β " *Cancer Res.* (1987) 47:6451-6458.

(List continued on next page.)

Primary Examiner—Robert D. Budens

Attorney, Agent, or Firm—Morrison & Foerster, LLP

[57] ABSTRACT

Monoclonal antibodies to transforming growth factor beta (TGF- β) are prepared from hybrid cell lines by immunizing with TGF- β_2 . The antibodies may be of any isotype and may be of any mammalian origin such as murine or human origin. Therapeutic applications utilizing the TGF- β monoclonal antibody are also disclosed.